Gs 441524

Manufactured by Biosynth

Sourced in United Kingdom

GS-441524 is a chemical compound that can be used as a research tool in laboratory settings. It is a synthetic analogue of a naturally occurring substance. The core function of GS-441524 is to serve as a chemical reagent for research and experimental purposes. No further details or interpretations about its intended use are provided.

Automatically generated - may contain errors

Lab products found in correlation

Remdesivir, by Biosynth (2 mentions) Celltiter 96 aqueous mts reagent, by Promega (2 mentions) Turbo dna free kit, by Thermo Fisher Scientific (2 mentions) Nanodrop, by Thermo Fisher Scientific (2 mentions) Trizol reagent, by Thermo Fisher Scientific (2 mentions) Pf 07321332, by Pfizer (1 mentions) Peg400, by Merck Group (1 mentions) Niclosamide, by Selleck Chemicals (1 mentions) Chloroquine, by MedChemExpress (1 mentions) Salinomycin, by MedChemExpress (1 mentions) Anisomycin, by Merck Group (1 mentions) Tilorone, by MedChemExpress (1 mentions) Homoharringtonine, by MedChemExpress (1 mentions) Valinomycin, by Merck Group (1 mentions) Oligomycin, by Merck Group (1 mentions) Crystal violet, by Merck Group (1 mentions) Nitazoxanide, by Selleck Chemicals (1 mentions) Atovaquone, by MedChemExpress (1 mentions) Vismodegib, by MedChemExpress (1 mentions) Antimycin a, by Merck Group (1 mentions)

6 protocols using gs 441524

Synthesis and Characterization of SARS-CoV-2 Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols

PF-07321332 was synthesized at TCG Lifesciences (India) and Wuxi (USA). In addition, a 1:1 MTBE solvate form of PF-07321332 was kindly provided by Pfizer. GS-441524 (the parent nucleoside analog of remdesivir) was purchased from Carbosynth (United Kingdom). For in vitro assays, compounds were dissolved in analytical grade dimethyl sulfoxide (DMSO) to 10 mM stock solution. For in vivo studies, the Beta variant efficacy studies were performed with both PF-07321332 (TCG Lifesciences) and the MTBE solvate form from Pfizer. PF-07321332 (TCG Lifesciences) was formulated as 40 mg/ml in a vehicle containing 40% PEG400 (Sigma) in sterile distilled water. The MTBE solvate form (Pfizer) was formulated as 40 mg/ml suspension in 2% (v/v) Tween80 in 98% (v/v) of 0.5% (w/v) methylcellulose by geometric dilution. PF-07321332 (from Wuxi) was used only in the delta variant hamster study and it was formulated as 40 mg/ml in a vehicle containing 60% PEG400 (Sigma) in sterile distilled water. In these studies, the crystalline form of the active product ingredient (API) was characterized by differential scanning calorimetry (DSC) (data not shown). X-ray powder diffraction (XRPD) would be however required to fully characterize the crystalline form of each API used in in vivo studies.

Abdelnabi R., Foo C.S., Jochmans D., Vangeel L., De Jonghe S., Augustijns P., Mols R., Weynand B., Wattanakul T., Hoglund R.M., Tarning J., Mowbray C.E., Sjö P., Escudié F., Scandale I., Chatelain E, & Neyts J. (2022). The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern. Nature Communications, 13, 719.

+ Open protocol

+ Expand

Preparation of GS-441524 and ICZ stocks

Check if the same lab product or an alternative is used in the 5 most similar protocols

GS-441524 was purchased from Carbosynth Limited(Berkshire, United Kingdom). GS-441524 was prepared as 2 mM stocks in dimethyl sulfoxide (DMSO). ICZ was purchased from Janssen Pharma-central K. K. (Tokyo, Japan). ICZ was dissolved as 10 mM stocks in 40% (w/v) hydroxypropyl-beta-cyclodextrin (HβCD) solution.

Doki T., Takahashi K., Hasegawa N, & Takano T. (2022). In vitro antiviral effects of GS-441524 and itraconazole combination against feline infectious peritonitis virus. Research in Veterinary Science, 144, 27-33.

+ Open protocol

+ Expand

Comprehensive Chemical Compound Library

Check if the same lab product or an alternative is used in the 5 most similar protocols

Emetine (HY–B1479A, 99.81%, LCMS), salinomycin (HY-15597, >98%, NMR), tilorone (HY–B1080, 99.9%, LCMS), chloroquine (HY-17589, 99.9%, LCMS), homoharringtonine (HY-14944, 99.2%, LCMS), gemcitabine (HY–B0003, 99.9%, LCMS), vismodegib (HY-10440, 99.9%, LCMS), conivaptan (HY-18347A, 99.9%, LCMS), and atovaquone (HY-13832, 99.8%, LCMS) were purchased from MedChem Express (Monmouth Junction, NJ, USA); niclosamide (S3030, 99.8%, HPLC) and nitazoxanide (S1627, 99.3%, HPLC) were from Selleckchem (Houston, TX, USA); antimycin A (A8674, 97.64%, HPLC), anisomycin (A9789, >98%, HPLC) oligomycin (O4876, >90%, HPLC), valinomycin (V0627, ≧90%, HPLC) and crystal violet (C0775, Dye content ≥90%) were from Sigma–Aldrich (St. Louis, MO, USA); GS-441524 (AG167808, >98%, HPLC) were from Carbosynth (San Diego, CA, USA). All chemicals were used as supplied.

Yang C.W., Peng T.T., Hsu H.Y., Lee Y.Z., Wu S.H., Lin W.H., Ke Y.Y., Hsu T.A., Yeh T.K., Huang W.Z., Lin J.H., Sytwu H.K., Chen C.T, & Lee S.J. (2020). Repurposing old drugs as antiviral agents for coronaviruses. Biomedical Journal, 43(4), 368-374.

+ Open protocol

+ Expand

Hamster SARS-CoV-2 Infection Modeling Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

PBS was purchased from Merck. Male Syrian golden hamsters were purchased from Janvier Labs. Swabs (1 mL Liquid Amies Regular Flocked) were purchased from Appleton Woods. GoTaq^® Probe 1-Step RT–qPCR System was purchased from Promega. SARS-CoV-2 (2019-nCoV) CDC qPCR Probe Assay, CDC RUO 2019-nCoV_N_Positive Control and the SARS-CoV-2 E SgRNA were purchased from IDT. TRIzol reagent, GlycoBlue^™, Phasemaker^™ tubes, Nanodrop and TURBO DNA-free^™ kit were purchased from Thermo Fisher. A bead mill homogenizer was purchased from Fisher Scientific. Precellys CKMix lysing tubes were purchased from Bertin Instruments. A Chromo4^™ Real-Time PCR Detector was purchased from Bio-Rad. Transmission cages were purchased from Tecniplast UK Ltd. GS-441524 was purchased from Carbosynth (UK).

Box H.J., Sharp J., Pennington S.H., Kijak E., Tatham L., Caygill C.H., Lopeman R.C., Jeffreys L.N., Herriott J., Neary M., Valentijn A., Pertinez H., Curley P., Arshad U., Rajoli R.K., Jochmans D., Vangeel L., Neyts J., Chatelain E., Escudié F., Scandale I., Rannard S., Stewart J.P., Biagini G.A, & Owen A. (2023). Lack of antiviral activity of probenecid in vitro and in Syrian golden hamsters. Journal of Antimicrobial Chemotherapy, 79(1), 172-178.

+ Open protocol

+ Expand

SARS-CoV-2 Cell-Based Antiviral Assay

Cited 2 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

We purchased HCoV-229E and human embryonic lung (HEL) fibroblast cells from ATCC (VR-740 and CCL-137). To conduct the cytopathic effect (CPE) reduction assay [57 (link)], confluent HEL cell cultures in 96-well plates were exposed to serial compound dilutions and immediately infected with HCoV-229E (MOI: 100 CCID₅₀ per well). At the same time, we added the compounds to mock-infected plates to measure cytotoxicity. After five days of incubation at 35 °C, the plates were submitted to microscopic scoring of CPE (virus-infected plates) and compound cytotoxicity (mock-infected plates). To quantify the results by MTS cell viability assay, the medium was replaced by CellTiter 96^® AQ_ueous MTS Reagent (from Promega) and, on the next day, optical density at 490 nm was measured in a plate reader. The 50% effective concentration (EC₅₀), based on microscopy or MTS assay, and the 50% cytotoxic concentration (CC₅₀) by MTS assay were calculated using reported formulas [58 (link)]. The cytotoxicity estimated by microscopy was expressed as the minimal cytotoxic concentration (MCC) causing visible alterations in cell morphology. We included two reference compounds: GS-441524 (the nucleoside form of remdesivir; from Carbosynth) and K22 [(Z)-N-[3-[4-(4-bromophenyl)-4-hydroxypiperidin-1-yl]-3-oxo-1-phenylprop-1-en-2-yl]benzamide [36 (link)]; from ChemDiv].

De Castro S., Stevaert A., Maldonado M., Delpal A., Vandeput J., Van Loy B., Eydoux C., Guillemot J.C., Decroly E., Gago F., Canard B., Camarasa M.J., Velázquez S, & Naesens L. (2022). A Versatile Class of 1,4,4-Trisubstituted Piperidines Block Coronavirus Replication In Vitro. Pharmaceuticals, 15(8), 1021.

+ Open protocol

+ Expand

Antiviral Assay for HCoV-229E

Check if the same lab product or an alternative is used in the 5 most similar protocols

HCoV-229E was purchased from ATCC (VR-740) and expanded in human embryonic lung fibroblast cells (HEL; ATCC ® CCL-137). The titers of virus stocks were determined in HEL cells and expressed as TCID 50 (50% tissue culture infective dose). 54 The cytopathic effect (CPE) reduction assay was performed in 96-well plates containing confluent HEL cell cultures, as previously described. 55 Serial compound dilutions were added together with HCoV-229E at an MOI of 100. In parallel, the compounds were added to a mock-infected plate to assess cytotoxicity. Besides the test compounds, two references were included, i.e. K22 [(Z)-N-[3-[4-(4-bromophenyl)-4-hydroxypiperidin-1-yl]-3-oxo-1-phenylprop-1-en-2-yl]benzamide; 47 from ChemDiv] and GS-441524 (the nucleoside form of remdesivir; from Carbosynth). After five days incubation at 35°C, microscopy was performed to score virus-induced CPE. To next perform the colorimetric MTS cell viability assay, the reagent (CellTiter 96 ® AQ ueous MTS Reagent from Promega) was added to the wells, and 24 h later, absorbance at 490 nm was measured in a plate reader. Antiviral activity was calculated from three independent experiments and expressed as EC 50 or concentration showing 50% efficacy in the MTS or microscopic assay (see reference 56 for calculation details). Cytotoxicity was expressed as 50% cytotoxic concentration (CC 50 ) in the MTS assay.

Stevaert A., Krasniqi B., Van Loy B., Nguyen T., Thomas J., Vandeput J., Jochmans D., Thiel V., Dijkman R., Dehaen W., Voet A, & Naesens L. (2021). Betulonic Acid Derivatives Interfering with Human Coronavirus 229E Replication via the nsp15 Endoribonuclease. Journal of medicinal chemistry, 64(9).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!